Hologic (HOLX) Divests Cynosure To Focus On Women's Health
Zacks Investment Research | Jan 01, 2020 09:14PM ET
Hologic, Inc. (NASDAQ:HOLX) recently completed the earlier-announced divestiture of the Cynosure medical aesthetics business. Per the terms of the deal, the company sold Cynosure to Clayton, Dubilier & Rice for a total purchase price of $205 million in cash. After certain adjustments, net receivables in cash were $142 million, at the closing of the transaction.
Per the terms of the agreement, roughly 825 employees will be transferred with the Cynosure business.With the divestment, the company expects to witness favorable outcomes, as Cynosure had been significantly underperforming since its acquisition in March 2017.
Rationale Behind the Divestment
Hologic’s management believes that divesting the medical aesthetics business will enable it to focus more on other core business segments, including Breast Health, which currently accounts for more than 38% of total revenues.
Meanwhile, the company aims at focusing on smaller tuck-in deals, thereby strengthening its core franchises.
Financial Impact of the Deal
As stated by the company earlier, this transaction is expected to result in significant additional non-cash impairment charges, which will be reflected in GAAP results for fourth-quarter fiscal 2019.
Hologic expects additional pre-tax impairment charges of $155-$185 million for fourth-quarter fiscal 2019 to reduce the carrying value of the asset group to its fair value. Following this, the asset group is expected to meet the desired criteria by first-quarter fiscal 2020.
However, these adjustments could result in further expenses. Additionally, the loss from the divestment is expected to generate a cash tax refund of $300 million in calendar year 2022.
In fiscal 2020, the full impact of the latest divestment and its accelerated share repurchase program are expected to be reflected in the form of raised earnings per share on both GAAP and non-GAAP basis.
Price Performance
The company’s shares have risen 36.4% in the past year compared with the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.